Results 191 to 200 of about 60,295 (253)

International Expert Opinion on Optimal Switching to Cladribine Tablets from Other High-Efficacy Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis: Opportunities and Challenges. [PDF]

Neurol Ther
Chan A, Alroughani R, Calabrese M, Havrdová EK, Obeidat AZ, Schmierer K, Andersson M, Bek L, Savarin C, Korich J, Bonsignore L, de Seze J.   +11 more
europepmc   +1 more source

Single versus repeated intravenous oncolytic reovirus infusions: Implications for immune modulation and rationalised scheduling of therapy in hepatocellular carcinoma

International Journal of Cancer, Volume 158, Issue 12, Page 3252-3267, 15 June 2026.
What's new? Oncolytic viruses are a promising immunotherapeutic approach against many malignancies. However, it is unclear whether repeated doses have improved therapeutic value or may trigger greater side effects, especially in patients with hepatocellular carcinoma whose liver is chronically damaged.
Karen J. Scott, Emma J. West, Rebecca J. Brownlie, Fay Ismail, Christy Ralph, Thomas Heineman, Matt Coffey, Alan A. Melcher, Alison Taylor, Salvatore Papa, Adel Samson   +10 more
wiley   +1 more source

The neutrophil-to-lymphocyte ratio as a marker of immunosenescence and COVID-19 outcomes in the elderly: A narrative review. [PDF]

Physiol Rep
Gasmi M, Torabinasab K, Williams-Hooker R, Marsigliante S, Muscella A.   +4 more
europepmc   +1 more source

Treatment-free remission in MS: long-term disease control with cladribine tablets. [PDF]

J Neurol
Wiendl H, Gold R, Pul R, Ernst M, Kowarik MC, Klehmet J, Siglienti I, Hübschen M, Wagner T, Knaup J, Kleinschnitz C.   +10 more
europepmc   +1 more source

Late-onset combined immunodeficiency and bone marrow failure in severe autoimmune hepatitis: a case report. [PDF]

J Med Case Rep
Sahbani F, Hajer H, Zehani A, Dabbebi H, Yacoub H, Cherif D, Maamouri N, Kchir H.   +7 more
europepmc   +1 more source

Impact of lymphopenia and hypogammaglobulinemia on outcomes in neutropenic patients with hematological malignancies. [PDF]

Int J Hematol
Van de Louw A, King L, Nickolich M.
europepmc   +1 more source

Sequential chemo-durvalumab, reduced-dose RT, and consolidation durvalumab for unresectable stage III NSCLC unfit for PACIFIC regimen (DEDALUS trial). [PDF]

JNCI Cancer Spectr
Agustoni F, Saddi J, Cortinovis DL, Arcangeli S, Sala L, Klersy C, Musella V, Galli G, Borgetto SMC, Stella GM, Cicognini D, Ferrari A, Pedrazzoli P, Grossi F, Filippi AR.   +14 more
europepmc   +1 more source

Ramsay-Hunt Syndrome in Patients Undergoing Dose-Dense Chemotherapy in the Perioperative Period of Breast Cancer: Two Case Reports. [PDF]

Cureus
Kanaya E, Matsui K, Urasaki A, Furukawa M, Nagasawa S, Araki M, Sekine S, Fujii T.   +7 more
europepmc   +1 more source

Dominant-negative PSMB10 disrupts immunoproteasome assembly and leads to transient T lymphopenia. [PDF]

J Hum Immun
Ghosh S, Wang Y, Schultheiss C, Borkhardt A, Dafun AS, Knipp L, Marwitz S, Ehl S, Soulard C, Haddad E, Dey D, Evans G, Golwala ZM, Bennstein SB, Laws HJ, Rohlfs M, Magg T, Binder M, Kreins AY, Bousquet MP, Marcoux J, Klein C, Conn GL, Meiners S, Hauck F.   +24 more
europepmc   +1 more source

Siponimod for relapsing-remitting multiple sclerosis: a single-center, real-world cohort study in China. [PDF]

BMC Neurol
Tan H, Zhou L, Gao Y, Zhao C, Lu C, Dong Q, ZhangBao J, Quan C.   +7 more
europepmc   +1 more source